AI Verdict
MELI has stronger fundamentals based on our AI analysis.
MELI vs MED Fundamental Comparison
| Metric | MELI | MED |
|---|---|---|
| Revenue | $28.9B | $385.8M |
| Net Income | $2.0B | $-18.7M |
| Net Margin | 6.9% | -4.8% |
| ROE | 29.6% | -9.4% |
| ROA | 4.7% | -7.5% |
| Current Ratio | 1.17x | 4.69x |
| Debt/Equity | 1.36x | 0.00x |
| EPS | $39.40 | $-1.70 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MELI vs MED: Frequently Asked Questions
Is MELI or MED a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MELI has stronger fundamentals. MELI is rated STRONG BUY (92% confidence) while MED is rated SELL (85% confidence). This is not investment advice.
How does MELI compare to MED fundamentally?
MERCADOLIBRE INC has ROE of 29.6% vs MEDIFAST INC's -9.4%. Net margins are 6.9% vs -4.8% respectively.
Which stock pays higher dividends, MELI or MED?
MELI has a dividend yield of N/A or no dividend while MED has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MELI or MED for long term?
For long-term investing, consider that MELI has STRONG BUY rating with 92% confidence, while MED has SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MELI vs MED?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MELI vs MED, the AI consensus favors MELI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.